K140377 is an FDA 510(k) clearance for the XTAG GASTROINTESTINAL PATHOGEN PANEL (GPP)/XTAG DATA ANALYSIS SOFTWARE FOR GP.... Classified as Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-based Assay System (product code PCH), Class II - Special Controls.
Submitted by Luminex Molecular Diagnostics, Inc. (Toronto, Ontario, CA). The FDA issued a Cleared decision on September 16, 2014 after a review of 214 days - an extended review cycle.
This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3990 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.
View all Luminex Molecular Diagnostics, Inc. devices
NCT01326013
Completed
Observational
Industry-sponsored
A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel
A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel (xTAG GPP) in Patients With Signs and Symptoms of Infectious Colitis and Gastroenteritis
| Condition studied |
Infectious; Colitis; Gastroenteritis |
| Eligibility |
All sexes
|
| Principal investigator |
Jeremy Liu, Ph.D |
| Sponsor |
Luminex Molecular Diagnostics
(industry)
|
Started 2011-06-01
→
Primary completion 2012-02-01
→
Completed 2012-03-01
Study completed - no results published.
This trial concluded in 2012 but has not posted
results to ClinicalTrials.gov. Completed studies without public results are common
in industry-sponsored device trials; the data may be referenced in the
510(k) Summary PDF or remain unpublished.
View full study on ClinicalTrials.gov